Whole-genome sequencing demonstrates that fidaxomicin is superior to vancomycin for preventing reinfection and relapse of infection with clostridium difficile

Journal of Infectious Diseases

Volumn 209, Issue 9, 2014, Pages 1446-1451

  Eyre, David W ^a   Babakhani, Farah ^b   Griffiths, David ^a   Seddon, Jaime ^b   Del Ojo Elias, Carlos ^a   Gorbach, Sherwood L ^b   Peto, Tim E A ^a   Crook, Derrick W ^a   Walker, A Sarah ^a  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^b Optimer Pharmaceuticals   (United States)

Author keywords

Clostridium difficile; fidaxomicin; recurrence; whole genome sequencing

Indexed keywords

CLOSTRIDIUM DIFFICILE; FIDAXOMICIN; RECURRENCE; WHOLE GENOME SEQUENCING;

AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; DNA, BACTERIAL; DOUBLE-BLIND METHOD; DRUG RESISTANCE, BACTERIAL; GENOME, BACTERIAL; HUMANS; POLYMORPHISM, SINGLE NUCLEOTIDE; RECURRENCE; SEQUENCE ANALYSIS, DNA; VANCOMYCIN;

EID: 84898883105     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jit598     Document Type: Article

References (15)

1. Louie TJ, Miller MA, Mullane KM, et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 2011; 364:422-31
2. Cornely OA, Crook DW, Esposito R, et al. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: A double-blind, non-inferiority, randomised controlled trial. Lancet Infect Dis 2012; 12:281-9
3. Crook DW, Walker AS, Kean Y, et al. Fidaxomicin versus vancomycin for Clostridium difficile infection: Meta-Analysis of pivotal randomized controlled trials. Clin Infect Dis 2012; 55:S93-103
4. Eyre DW, Walker AS, Griffiths D, et al. Clostridium difficile mixed infection and reinfection. J Clin Microbiol 2012; 50:142-4
5. Figueroa I, Johnson S, Sambol SP, Goldstein EJC, Citron DM, Gerding DN. Relapse versus reinfection: Recurrent Clostridium difficile infection following treatment with fidaxomicin or vancomycin. Clin Infect Dis 2012; 55 (Suppl 2):S104-9
6. Didelot X, Eyre DW, Cule ML, et al. Microevolutionary analysis of Clostridium difficile genomes to investigate transmission. Genome Biol 2012; 13:R118
7. Eyre DW, Cule ML, Wilson DJ, et al. Whole genome sequencing reveals diverse sources for C. difficile infection. N Engl J Med 2013; 369: 1195-205
8. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999; 94:496-509
9. Dificid (fidaxomicin) tablets [package insert]. San Diego, CA: Optimer Pharmaceuticals, May 2011
10. Louie TJ, Cannon K, Byrne B, et al. Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin reexpression and recurrence of CDI. Clin Infect Dis 2012; 55 (Suppl 2):S132-42
11. Chilton CH, Crowther GS, Freeman J, et al. Successful treatment of simulated Clostridium difficile infection in a human gut model by fidaxomicin first line and after vancomycin or metronidazole failure. J Antimicrob Chemother 2013. [Epub ahead of print]
12. Optimer Pharmaceuticals. Anti-infective drugs advisory committee meeting briefing document. 2011. http://www.fda.gov/downloads/Advisory Committees/CommitteesMeetingMaterials/Drugs/Anti-InfectiveDrugs AdvisoryCommittee/UCM249354.pdf. Accessed 10 March 2013
13. Eyre DW, Walker AS, Freeman J, et al. Short-Term genome stability of serial Clostridium difficile ribotype 027 isolates in an experimental gut model and recurrent human disease. PLoS One 2013; 8:e63540
14. Eyre DW, Cule ML, Griffiths D, et al. Detection of mixed infection from bacterial whole genome sequence data allows assessment of its role in Clostridium difficile transmission. PLoS Comput Biol 2013; 9: E1003059
15. Eyre DW, Walker AS, Wyllie D, et al. Predictors of first recurrence of Clostridium difficile infection: Implications for initial management. Clin Infect Dis 2012; 55:S77-87.